Table 2.
Effects of polydatin in the protection and treatment of oxidative stress-associated liver diseases.
| Liver disease type | Experimental model | Dose and formulation | Duration of treatment | References | ||
|---|---|---|---|---|---|---|
| Alcohol liver diseases | Animals | Male Wistar rats | Ethanol/7 mL/kg/every 12 h/(i.g.) | 25, 50, and 100 mg/kg/day/(i.g.) | Pretreatment for 7 days | [41] |
| Hepatic steatosis | Animals | Zebrafish strain | Ethanol/350 mM (2% EtOH)/32 h at 28.5°C | 6.25, 12.5, 25 μg/mL | 48 h | [42] |
| Acute liver injury | Animals | C57BL/6 male mice | Ethanol/50%/10 mL/kg/oral/2 days | 50 and 100 mg/kg/day (i.g.) | Pretreatment for 8 days | [46] |
| Nonalcohol fatty liver | Animals | Male Sprague Dawley rats | High-fat diet/12 weeks | 0.3%/day (i.g.) | 12 weeks | [55] |
| Nonalcohol fatty liver | Animals | Male Sprague Dawley rats | Fructose-induced/drinking 10% Fructose/6 weeks |
7.5, 15, 30 mg/kg (i.g.) | 7 weeks | [56] |
| Cells | BRL-3A/HepG2 | 4.5 mg/mL glucose/12 h | 10, 20, and 40 μM | 24 h | ||
| Nonalcoholic steatohepatitis | Animals | C57BL/6 male mice | Methionine-choline deficient diet/4 weeks | 5 mg/kg (i.p.) | 4 weeks | [59] |
| Cells | HepG2 cells | 250 μM palmitic acid/24 h | 5, 10, and 20 μM | 24 h | ||
| Nonalcohol fatty liver | Animals | Male Sprague Dawley rats | High-fat diet/16 weeks | 30, 90 mg/kg/day/(i.g.) | 8 weeks | [60] |
| Nonalcohol fatty liver | Animals | Male C57/BL6 mice | High-fat diet/14 weeks | 100 mg/kg/day/(i.g.) | 4 weeks | [61] |
| NASH | Animals | C57Bl/KsJ-db/db (db/db) mice | Methionine-choline deficient/4 weeks | 100 mg/kg/(i.g.) | Every other day for 4 weeks | [63] |
| Cells | L02 cells | Palmitic acid/60 μg/mL/24 h | 24 μM | 24 h | ||
| Liver injury | Animals | Male ICR mice | APAP/220 mg. kg−1/i.p. | 25, 50, and 100 mg/kg/day/(i.g.) | Pretreatment for 7 days | [66] |
| Liver injury | Animals | Male Wistar albino rats | Cis/7 mg/kg/i.p. | 25, 50, and 100 mg/kg/day/(i.g.) | Pretreatment for 10 days | [67] |
| Liver injury | Animals | Male ICR mice | Sulfur mustard/40 mg/kg/i.p. | 100, 200, and 400 mg/kg/day | 7 days | [70] |
| Cells | L02 cells | Sulfur mustard/50 μM/30 min | 50 μM | 24 h | ||
| Liver injury | Animals | Male ICR mice | CCl4/5 μL/kg/i.p. | 25, 50, and 100 mg/kg/day/(i.g.) | Pretreatment for 5 days | [72] |
| Liver injury | Animals | Male Wistar albino rats | As/100 mg/L/drinking | 50, 100, and 200 mg/kg/day/(i.g.) | 60 days | [75] |
| Liver injury | Animals | Male Wistar albino rats | Cadmium chloride/5 mg/kg/gastric gavage/4 weeks | 120 mg/kg/day/(i.g.) | 4 weeks | [77] |
| Fulminant hepatic failure | Animals | Balblc mice | LPS (50 μg/kg) and D − GaIN (700 mg/kg)/i.p. | 10, 30, 100 mg/kg/day/i.p. | Pretreatment for 1 h | [84] |
| Liver injury | Animals | Male C57BL/6 mice | ANIT/60 mg/kg/48 h (i.g.) | 40, 60, and 80 mg/kg/day/(i.g.) | Pretreatment for 7 days | [90] |
| Liver fibrosis | Animals | C57BL/6 mice | CCl4/5 ml/kg/i.p./twice a week for 6 weeks | 5 mg/kg/(i.p.) | 3 and 6 weeks | [91] |
| Liver fibrosis | Animals | C57BL/6 mice | CCl4/50 μL/kg/i.p./twice a week for 6 weeks | 5 mg/kg/(i.p.) | 6 weeks | [93] |
| Cells | LX − 2 cells | PDGF − BB/10 ng/mL | 10 μM | 24 h | ||
| Liver fibrosis | Animals | Male Sprague Dawley rats | Fructose/10%/6 weeks/(i.g.) | 7.5, 15, and 30 mg/kg/(i.g.) | 11 weeks | [99] |
| Cells | BRL − 3A cells | Fructose/5 mM | 10, 20, and 40 μM | 6, 12, 24 h | ||
| Hepatocellular carcinoma | Animals | Male BALB/c nude mice | HepG2 cells/5 × 106/subcutaneous injection/120 mm3 | 25, 50, and 100 mg/kg/100 μL (i.p.) | 20 days | [104] |
| Cells | HepG2and SMMC − 7721 | 1, 3, 10, 30, and 100 mM | 48 h | |||